Disease | pleural effusion disorder |
Phenotype | C0149925|small cell lung cancer |
Sentences | 10 |
PubMedID- 20819493 | Objective: to compare the therapeutic effects of pleural perfusion of ndp and cddp in non-small cell lung cancer (nsclc) patients with malignant pleural effusion, their quality of life and toxic side effects. |
PubMedID- 23523589 | The diagnostic value of apolipoprotein e in malignant pleural effusion associated with non-small cell lung cancer. |
PubMedID- 26323029 | Purpose to determine the frequency and investigate possible mechanisms and prognostic relevance of minimal (<10-mm thickness) pleural effusion in patients with small cell lung cancer (sclc). |
PubMedID- 20207133 | Purpose: to investigate the feasibility, pharmacokinetics, efficacy and toxicity of intrapleural paclitaxel liposome injection in non-small cell lung cancer (nsclc) patients with malignant pleural effusions. |
PubMedID- 23925664 | Vascular endothelial growth factor (vegf) is involved in non-small cell lung cancer (nsclc) with malignant pleural effusion (mpe), but little is known regarding the efficacy of bevacizumab (bev) with carboplatin-paclitaxel (cp) for nsclc with mpe. |
PubMedID- 24758329 | Prognostic value of secreted phosphoprotein-1 in pleural effusion associated with non-small cell lung cancer. |
PubMedID- 26005243 | The patients studied here are enrolled in a phase i clinical trial of hpph-mediated pdt for the treatment of non-small cell lung cancer with pleural effusion. |
PubMedID- 21625182 | Predictive value of f-18 fdg pet/ct for malignant pleural effusion in non-small cell lung cancer patients. |
PubMedID- 23898708 | However, this condition is sometimes discovered, with or without a small amount of pleural effusion, at thoracotomy in patients with resectable non-small cell lung cancer. |
PubMedID- 25999646 | Patients in this study are enrolled in a phase i clinical trial of hpph-mediated pdt for the treatment of non-small cell lung cancer with pleural effusion. |
Page: 1